SCHEMBL5517606

SCHEMBL5517606

CCOC(=O)c1nn(COC(=O)OCC(C)C)nc1C(=O)c1cc(OC)c(OC)cc1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 3/20 0.35
HPGD P15428 2/20 0.35
POLB P06746 1/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
MAPT P10636 3/20 0.34
DPP4 P27487 2/20 0.34
HTT P42858 1/20 0.34
LMNA P02545 1/20 0.34
SLC5A1 P13866 2/20 0.34
SLC5A2 P31639 2/20 0.34
CSNK1D P48730 1/20 0.34
NPSR1 Q6W5P4 2/20 0.33
PRKCZ Q05513 1/20 0.33
GAA P10253 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5516130 0.92 KDM4E (0.42) KDM4EALDH1A1HPGDPOLBMAPK1
SCHEMBL5508711 0.89 KDM4E (0.38) KDM4EALDH1A1HPGDPOLBMAPK1
SCHEMBL5511556 0.88 KDM4E (0.40) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL5512857 0.86 KDM4E (0.38) KDM4EALDH1A1SMN1; SMN2MAPTDPP4
SCHEMBL5511474 0.86 KDM4E (0.40) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL5512207 0.86 MYC (0.42) KDM4EALDH1A1HPGDPOLBMAPK1
SCHEMBL5517871 0.85 POLB (0.43) KDM4EALDH1A1POLBSMN1; SMN2MAPT
SCHEMBL5524869 0.85 KDM4E (0.39) KDM4EALDH1A1POLBMAPTDPP4
SCHEMBL5524774 0.85 KDM4E (0.43) KDM4EALDH1A1HPGDPOLBMAPK1
SCHEMBL5512916 0.84 KDM4E (0.44) KDM4EALDH1A1HPGDPOLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238812-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEJI SEIKA KAISHA, LTD. (JP) 2007-07-03 US disclosed
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2006-04-06 US disclosed
US-7022860-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
EP-1026167-B1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND ANTIALLERGIC AGENTS MEIJI SEIKA KAISHA (JP) 2003-03-05 EP disclosed
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2002-09-26 US disclosed
US-6372735-B1 ANTIHISTAMINES MEIJI SEIKA KAISHA, LTD. (JP) 2002-04-16 US disclosed
EP-1026167-A1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND ANTIALLERGIC MEIJI SEIKA KAISHA LTD. (JP) 2000-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP2D6, CYP2B6 KDM4E 752/4885ALDH1A1 959/4885HPGD 910/4885
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP3A4, TPH1 KDM4E 547/4885ALDH1A1 691/4885HPGD 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.